IMAAVY demonstrated a swift and significant decrease in IgG levels, a primary driver of gMG, in key adult and pediatric trials.
Regulatory Approval
Adult GCA can now be treated with RINVOQ (upadacitinib), the first and only oral Janus Kinase (JAK) inhibitor authorized for this purpose.
Columvi therapy provides a much-needed, off-the-shelf, fixed-duration alternative for transplant ineligible individuals.
Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
Lecanemab is the only approved Aβ monoclonal antibody that binds and clears hazardous protofibrils.
IgG4-RD can arise in various organs, causing fibrosis and irreversible organ damage. Understanding how organ damage occurs is key to making an accurate diagnosis of IgG4-RD.
Pfizer Inc (PFI). announced that the European Commission (EC) has amended the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to include the prevention of RSV-induced lower respiratory tract disease (LRTD) in people aged 18 to 59. This broadens the prior license for […]
In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.
Approval based on data from the pivotal phase III EAGLE-2 and EAGLE-3 trials.
The European Commission is currently taking final action on the application for the use of Jaypirca in patients with relapsed or refractory CLL who have received prior treatment with a BTK inhibitor as a result of this favorable view.
